Fig. 1From: Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experiencePrimary outcome: Percentage of responders at the end of the third (T1) and of the sixth month (T2) of erenumab administrationBack to article page